Pevion Biotech announced today that two components of its prophylactic malaria vaccine PEV3A successfully finished a Phase I clinical trial. The trial was initiated in November 2003 and designed to evaluate safety, tolerability and immunogenicity of its vaccine when administered at different dose levels. Vaccination at all dose levels was well tolerated in all subjects and generated a long lasting and specific antibody immune response. The positive results allowed a rational design for the ongoing Phase IIa study.
